DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Iron Deficiency Anemia-Pipeline Insights, 2016" report to their offering.
The report provides in depth insight on the pipeline drugs and their development activities around the Iron Deficiency Anemia. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.
The report covers the product clinical trials information and other development activities including technology, licensing, collaboration, acquisitions, funding, patent and USFDA & EMA designations details. The report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Iron Deficiency Anemia.
Reasons to buy:
- Complete Pipeline intelligence and complete understanding over therapeutic development for Iron Deficiency Anemia.
- Identify the relationship between the drugs and its use for target finding, drug re-purposing, and precision medicine.
- Devise corrective measure for pipeline projects by understanding Iron Deficiency Anemia pipeline depth and focus of Indication therapeutics.
- Developing strategic initiatives to support your drug development activities.
- Optimizing the portfolio and keep in touch with the rapid changing pharmaceutical market, and make the best decision for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Provides strategically significant competitor information, analysis, and insight to formulate effective R&D development strategies.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
-
Gaining a clear picture of the competitive landscape for evidence
based decisions.
Key Topics Covered:
- Overview
- Pipeline Therapeutics
- Therapeutics under Development by Companies
- Filed and Phase III Products
- Phase II Products
- Phase I and IND Filed Products
- Discovery and Pre-Clinical Stage Products
- Drug Candidate Profiles
- Iron Deficiency Anemia - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Iron Deficiency Anemia - Discontinued Products
- Iron Deficiency Anemia - Dormant Products
-
Companies Involved in Therapeutics Development for Iron Deficiency
Anemia
For more information visit http://www.researchandmarkets.com/research/rgfwl7/iron_deficiency
